Saturday 17 October 2026
Export IONS’s income statement to Excel — free account
Ionis Pharmaceuticals, Inc.
IONS Healthcare Biotechnology
Ionis Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $943.7 million, up 33.8% from fiscal 2024. In the quarter to June 2026, revenue fell 40.7%, EPS fell 188.5%, free cash flow grew 299.3% and total debt rose 116.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
42.94
1.18
−2.67%
Follow IONS
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 723.20 | 27.17 | 28.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
3 | 6 | 6 | 6 | 4 | 6 | 1 | 4 | 2 | 4 |
P/S ratio |
15.36 | 11.88 | 11.93 | 7.53 | 10.82 | 5.29 | 9.08 | 9.61 | 7.41 | 13.41 |
Altman Z-Score |
3.67 | 3.90 | 3.41 | 4.60 | 3.05 | 2.02 | 1.44 | 1.58 | 0.89 | 2.12 |
P/FCF ratio |
0.00 | 44.81 | 12.22 | 27.34 | 0.00 | 367.72 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
0.53 | 2.09 | 4.25 | 6.16 | 2.65 | 4.20 | 2.28 | 2.22 | 1.80 | 1.12 |
Beneish M-Score |
3.85 | (3.38) | (2.12) | 0.08 | (3.69) | (2.69) | (2.38) | (0.61) | (2.46) | (3.13) |
P/Operating CF |
(213.31) | 299.39 | 61.93 | 30.44 | 80.57 | 21.07 | (26.63) | 230.35 | (45.01) | (91.92) |
P/B ratio |
57.50 | 16.72 | 6.03 | 5.02 | 10.62 | 5.56 | 9.30 | 19.58 | 8.88 | 25.88 |
Price to Tangible BV |
72.29 | 17.79 | 6.15 | 5.10 | 11.03 | 5.78 | 9.81 | 21.20 | 9.35 | 27.55 |
EV/Sales |
14.96 | 11.07 | 9.53 | 6.01 | 9.52 | 4.21 | 7.72 | 8.27 | 5.98 | 12.46 |
EV/EBITDA |
202.83 | 69.13 | 0.00 | 17.88 | 0.00 | 281.50 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(49.74) | 32.69 | 9.48 | 19.52 | 193.38 | 110.67 | (16.53) | (21.18) | (8.42) | (43.79) |
EV/FCF |
(45.11) | 41.77 | 9.77 | 21.81 | (1,346.18) | 292.06 | (108.29) | (19.41) | (7.65) | (36.11) |
Quick Ratio |
5.78 | 4.46 | 7.48 | 9.39 | 3.29 | 9.05 | 6.46 | 5.42 | 7.73 | 3.51 |
Current Ratio |
5.96 | 4.80 | 7.88 | 9.97 | 3.56 | 9.75 | 7.07 | 5.90 | 8.47 | 3.83 |
Net Debt/EBITDA |
(5.40) | (5.04) | 97.89 | (4.54) | 6.80 | (72.92) | 2.12 | 2.99 | 2.17 | 2.39 |
Debt/Assets |
56.63% | 45.92% | 24.24% | 24.36% | 39.32% | 47.18% | 46.99% | 42.60% | 41.47% | 50.50% |
Debt/Equity |
5.19 | 1.66 | 0.54 | 0.47 | 1.26 | 1.60 | 2.08 | 3.29 | 2.12 | 3.64 |
Asset Turnover |
0.40 | 0.46 | 0.30 | 0.38 | 0.26 | 0.32 | 0.23 | 0.29 | 0.24 | 0.29 |
Operating CF/Net income |
1.86 | 503.32 | 2.20 | 1.24 | (0.08) | (1.08) | 1.02 | 0.84 | 1.10 | 0.70 |
Capex/Depreciation |
(0.24) | (0.74) | (0.38) | (3.17) | (1.29) | (0.42) | 6.71 | 491.04 | 5.56 | (9.73) |
Interest Coverage |
(0.52) | 0.69 | (1.37) | 29.41 | (18.09) | (3.23) | (50.50) | (4.34) | (5.25) | (4.22) |
| (40.22%) | 0.15% | 35.27% | 19.37% | (36.60%) | (3.78%) | (40.12%) | (76.34%) | (93.10%) | (70.80%) | |
| (6.49%) | 0.03% | 13.72% | 9.43% | (15.80%) | (1.14%) | (10.48%) | (13.26%) | (15.15%) | (11.69%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(7.98%) | 0.03% | 13.29% | 10.69% | (25.94%) | (1.25%) | (13.72%) | (16.17%) | (18.87%) | (16.35%) |
Average Days of Receivables |
105.79 | 44.69 | 7.77 | 20.49 | 38.14 | 27.88 | 15.87 | 45.31 | 47.72 | 25.55 |
Research and Development Expense of Revenue |
92.37% | 72.86% | 69.14% | 41.48% | 73.37% | 79.39% | 141.84% | 114.22% | 127.85% | 97.02% |
Selling, General and Administrative Expense of Revenue |
13.04% | 21.10% | 40.79% | 25.53% | 48.59% | 22.99% | 25.59% | 29.53% | 37.93% | 41.74% |
Intangible Assets out of Total Assets |
0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
19.34% | 16.72% | 21.90% | 13.06% | 31.55% | 14.89% | 17.07% | 13.43% | 18.46% | 14.19% |
Graham Net Nets |
0.00 | 0.03 | 0.10 | 0.14 | 0.06 | 0.12 | 0.05 | 0.01 | 0.04 | 0.00 |
Graham Number |
0.00 | 2.12 | 20.04 | 23.96 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(1.05%) | 0.14% | 3.68% | 3.51% | (5.73%) | (0.66%) | (5.06%) | (4.84%) | (8.70%) | (2.98%) |
Free Cash Flow Yield |
(2.16%) | 2.23% | 8.18% | 3.66% | (0.07%) | 0.27% | (0.79%) | (4.43%) | (10.55%) | (2.57%) |
Revenue per Share |
3.08 | 4.15 | 4.53 | 8.02 | 5.22 | 5.75 | 4.14 | 5.50 | 4.72 | 5.90 |
Operating CF per Share |
(0.93) | 1.40 | 4.56 | 2.47 | 0.26 | 0.22 | (1.93) | (2.15) | (3.35) | (1.68) |
Capex per Share |
(0.10) | (0.31) | (0.13) | (0.26) | (0.29) | (0.13) | 1.65 | (0.20) | (0.34) | (0.36) |
Free Cash Flow per Share |
(1.02) | 1.10 | 4.42 | 2.21 | (0.04) | 0.09 | (0.28) | (2.34) | (3.69) | (2.04) |
Cash per Share |
5.50 | 8.25 | 15.75 | 17.85 | 13.55 | 15.00 | 14.01 | 16.28 | 15.37 | 16.73 |
Shareholders Equity per Share |
0.82 | 2.95 | 8.97 | 12.03 | 5.32 | 5.47 | 4.04 | 2.70 | 3.94 | 3.06 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.82 | 2.95 | 8.97 | 12.03 | 5.32 | 5.47 | 4.04 | 2.70 | 3.94 | 3.06 |
Free Cash Flow |
(123.63) | 136.29 | 585.25 | 309.35 | (5.16) | 12.90 | (40.39) | (335.50) | (551.29) | (325.67) |
Working Capital |
664.15 | 925.12 | 1,927.59 | 2,447.59 | 1,531.81 | 2,104.50 | 1,891.13 | 2,193.76 | 2,310.97 | 2,209.07 |
Capital Expenditures |
(11.53) | (37.86) | (17.65) | (36.28) | (41.05) | (17.90) | 233.98 | (27.99) | (50.34) | (57.08) |
Net Current Asset Value |
(14.97) | 211.24 | 727.26 | 1,172.03 | 484.23 | 505.10 | 241.71 | 38.47 | 204.97 | (44.11) |
EV/EBIT |
0.00 | 183.35 | 0.00 | 18.44 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.03 | 0.07 | 0.03 | 0.03 | 0.06 | 0.02 | (0.40) | 0.04 | 0.07 | 0.06 |
Price to Operating Income |
0.00 | 196.73 | 0.00 | 23.11 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.51 | 0.42 | 0.35 | 0.07 | 0.18 | 0.24 | 0.47 | 0.00 | (0.10) | 0.05 |
Cash ROIC |
(9.65%) | 6.83% | 14.94% | 6.22% | (0.14%) | 0.31% | (1.08%) | (8.40%) | (13.34%) | (6.58%) |
Accounts Receivable Turnover |
6.24 | 6.01 | 15.84 | 29.62 | 10.48 | 11.74 | 13.44 | 12.77 | 7.42 | 11.93 |
Accounts Payable Turnover |
0.00 | 0.35 | 0.07 | 0.20 | 0.72 | 0.75 | 0.95 | 0.42 | 0.33 | 0.45 |
Inventory Turnover |
0.00 | 0.92 | 0.20 | 0.33 | 0.60 | 0.46 | 0.60 | 0.62 | 1.12 | 1.41 |
Average Days of Payables |
0.00 | 1,135.42 | 5,747.75 | 1,337.70 | 525.46 | 400.75 | 463.39 | 1,040.17 | 1,398.29 | 644.29 |
Days of Inventory on Hand |
0.00 | 455.43 | 1,721.12 | 1,513.62 | 671.07 | 835.10 | 569.71 | 297.38 | 407.21 | 230.53 |
Average Receivables |
59.70 | 85.50 | 37.86 | 37.90 | 69.62 | 69.05 | 43.72 | 61.66 | 94.98 | 79.12 |
Average Payables |
24.74 | 23.00 | 26.77 | 22.36 | 16.63 | 14.55 | 14.91 | 21.97 | 34.50 | 35.52 |
Average Inventory |
7.19 | 8.74 | 9.28 | 13.38 | 20.07 | 23.39 | 23.42 | 14.74 | 9.98 | 11.28 |
Average Assets |
930.18 | 1,117.62 | 1,995.28 | 2,950.45 | 2,811.43 | 2,500.72 | 2,572.78 | 2,761.97 | 2,996.87 | 3,263.76 |
Average Common Equity |
150.18 | 232.42 | 776.22 | 1,435.85 | 1,213.91 | 757.51 | 672.31 | 479.79 | 487.52 | 538.72 |
Columns are period end dates